메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Purpose: Allergen-specific immunotherapy (AIT) is the only curative treatment for allergic diseases, but a few allergic patients receiveAIT. In this multicenter cross-sectional study, we aimed to explore patient and physician perspectives on AIT through aquestionnaire survey. Materials and Methods: Allergic patients who received subcutaneous immunotherapy for at least 1 year were asked to answer aquestionnaire developed by an expert panel of allergen and immunotherapy workgroup in Korea. Results: A total of 267 patients (adults, 60.3%) with allergic rhinitis (91.4%), asthma (42.7%), or atopic dermatitis (20.2%) from referredhospitals completed the survey. Among patients and physicians, respectively, the overall rates of satisfaction with AIT for allergicrhinitis were 86.4% and 83.3% (kappa agreement=0.234, p<0.001), and those for asthma were 85.3% and 72.9% (kappa agreement=0.373, p<0.001). Moreover, pediatric asthmatic patients reported a significantly higher satisfaction rate than adult asthmaticpatients after AIT (p=0.040). Symptom severity (p<0.001, respectively) and drug use for allergic rhinitis and asthma decreased afterAIT. However, there was no significant difference in satisfaction rates between children and adults in allergic rhinitis (p=0.736). Interestingly,35.7% and 35% of allergic rhinitis and asthma patients, respectively, reported experiencing improvement in their symptomswithin 6 months of starting AIT. Conclusion: In this study evaluating the perspectives of patients and physicians on AIT, the majority of patients were satisfiedwith the efficacy and safety of AIT, but not its cost. AIT should be recommended for AR and allergic patients.

목차

등록된 정보가 없습니다.

참고문헌 (32)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0